Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00089869 · ClinicalTrials.gov registry record · Phase 1

A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia

A Phase 1 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 1
Development phase

NCT00089869: Completed Phase 1 study, sponsored by Eli Lilly and Company.

NCT00089869 is a Phase 1 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00089869, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 1
Development phase

Study Summary

Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

Interventions

  • DRUG placebo
  • DRUG olanzapine
  • DRUG atomoxetine

Trial Details

FieldValue
Phase Phase 1
Eli Lilly and Company

1,341 total trials

What the finished NCT00089869 record still lists

NCT00089869 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.

The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.

NCT00089869 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00089869 about?

NCT00089869 is a clinical study titled "A Combination of Two Currently Approved Drugs to Enhance the Treatment of Schizophrenia". Study of a medication for the treatment of Schizophrenia in patients who are already taking Abilify, Risperdal, Seroquel, Zyprexa

What is the current status of trial NCT00089869?

This trial is currently completed. It is a Phase 1 study.

What interventions are being tested in trial NCT00089869?

The interventions under investigation include: placebo (DRUG), olanzapine (DRUG), atomoxetine (DRUG).

Who is sponsoring clinical trial NCT00089869?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

Source: ClinicalTrials.gov NCT00089869, the US trial registry maintained by the National Library of Medicine. NCT00089869 (unsized enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.